Pluri Inc. (PLUR)
- Previous Close
6.12 - Open
6.48 - Bid --
- Ask 6.12 x 100
- Day's Range
5.94 - 6.48 - 52 Week Range
3.44 - 8.56 - Volume
12,462 - Avg. Volume
27,861 - Market Cap (intraday)
32.872M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-4.64 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
www.pluri-biotech.comRecent News: PLUR
Performance Overview: PLUR
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLUR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLUR
Valuation Measures
Market Cap
32.87M
Enterprise Value
36.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
92.58
Price/Book (mrq)
--
Enterprise Value/Revenue
108.35
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.85%
Return on Equity (ttm)
-154.87%
Revenue (ttm)
357k
Net Income Avi to Common (ttm)
-23.95M
Diluted EPS (ttm)
-4.64
Balance Sheet and Cash Flow
Total Cash (mrq)
30.62M
Total Debt/Equity (mrq)
460.30%
Levered Free Cash Flow (ttm)
-12.78M
Research Analysis: PLUR
Company Insights: PLUR
PLUR does not have Company Insights